Using our optimized staining protocol, on samples obtained using an enrichment methodology which depleted normal (RBCs and CD45 expressing) cells, we successfully illustrated the presence of γ-H2AX expression on CTCs in patients with metastatic breast cancer undergoing DNA damaging chemotherapy with platinums. The gene discussed is PTPRC; the disease is breast carcinoma.